review · Pharmaceuticals
Chrysoeriol is a natural flavone synthesised in multiple plant species, especially medicinal plants. Its concentration fluctuates according to the natural source, the specific plant part extracted, the geographical region, and the extraction and characterisation techniques applied. Research using in vitro and in vivo models indicates that chrysoeriol displays diverse pharmacological activities, including anticancer, anti-inflammatory, antibacterial, antifungal, neuroprotective, and anti-osteoporosis effects, alongside anti-insecticide properties. These actions operate across various subcellular, cellular, and molecular targets. Additionally, in vivo pharmacokinetic analyses show that the molecule possesses good stability. Owing to these characteristics, chrysoeriol demonstrates promising potential for the prevention and treatment of several serious health conditions, including cancer, diabetes, chronic inflammation, osteoporosis, cardiovascular diseases, and Parkinson's disease.
Chronic conditions such as diabetes, cardiovascular disease, and Parkinson's disease present significant global healthcare challenges. Identifying stable, naturally occurring compounds with wide-ranging therapeutic targets offers valuable leads for drug discovery. Demonstrating the biological stability and diverse pharmacological actions of chrysoeriol helps guide future investigations into natural molecules capable of addressing complex, multi-target diseases.
The compound could support drug discovery programmes within pharmaceutical and biotechnology companies developing treatments for cancer, diabetes, osteoporosis, or neurodegenerative disorders. Because the findings are derived from in vitro and in vivo preclinical studies alongside pharmacokinetic stability analyses, chrysoeriol remains at an early stage of research, requiring extensive formulation, safety testing, and clinical validation before reaching real-world therapeutic application.
AI-generated from the published abstract. Always read the original work before citing.
A flavone, chrysoeriol is synthetized in several plant species. It comes from several natural sources, especially medicinal plants. The identification and isolation of this compound has been carried out and verified by several research teams using different spectral methods. It seems that the concentration of this molecule is variable and fluctuating depending on the source, the part extracted, the region, and the methods of extraction and characterization. The aim of this paper is to highlight the in vitro and in vivo pharmacological properties of chrysoeriol and to provide insight into its pharmacokinetics. Anticancer, anti-inflammatory, antibacterial, antifungal, anti-osteoporosis, anti-insecticide, and neuroprotective actions have been shown in a number of studies on this chemical. Different mechanisms in theses pharmacological effects include subcellular, cellular, and molecular targets. In vivo pharmacokinetic analysis has proved the good stability of this molecule, showing its promising potential to prevent or treat diseases including cancer, diabetes, inflammation, osteoporosis, Parkinson's disease, and cardiovascular diseases.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph15080973
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
